Compounds > etoposide

Page last updated: 2024-08-23

etoposide and MS (Multiple Sclerosis)

etoposide has been researched along with MS (Multiple Sclerosis) in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (28.57)	29.6817
2010's	4 (57.14)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Ghraichy, M; Jelcic, I; Martin, R; Müller, AM; Ruder, J; Schanz, U; Trück, J; von Niederhäusern, V	1
Allen, CE; Andreassen, PR; Carroll, KR; Chaturvedi, V; Elfers, EE; Greenberg, JN; Henry, MM; Hermiston, ML; Hildeman, DA; Hogan, SP; Jordan, MB; Joyce, M; Kanter, J; Katz, JD; Ladisch, S; Lakes, N; McNally, JP; Millen, SH; Terrell, CE	1
Elfers, EE; Grunblatt, E; Hildeman, DA; Jordan, MB; Katz, JD; McNally, JP; Terrell, CE	1
Barreira, AA; Barros, GM; Barros, JC; Brum, DG; Burt, RK; Hamerschlak, N; Kutner, JM; Madeira, MI; Mastropietro, AP; Moraes, DA; Neto, JZ; Oliveira, EA; Oliveira, MC; Paes, AT; Pieroni, F; Porto, PP; Ribeiro, AA; Rodrigues, M; Santana, CL; Santos, AC; Simões, BP; Stracieri, AB; Tylberi, CP; Voltarelli, JC	1
Havrdová, E; Kemlink, D; Kobylka, P; Kovárová, I; Kozák, T; Krasulová, E; Lhotáková, P; Pohlreich, D; Trneny, M; Vacková, B	1
Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Marecková, H; Pit'ha, J; Pytlík, R; Vodvárková, S	1
Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Pit'ha, J; Pytlík, R; Vodvárková, S	1

Trials

3 trial(s) available for etoposide and MS (Multiple Sclerosis)

Article	Year
Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone marrow transplantation, 2010, Volume: 45, Issue:2 Topics: Adult; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Rejection; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Horses; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Quality of Life; Rabbits; Transplantation Conditioning	2010
High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone marrow transplantation, 2000, Volume: 25, Issue:5 Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carmustine; CD4-CD8 Ratio; Cytarabine; Etoposide; Female; Fever; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Leukapheresis; Lymphocyte Subsets; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis; Neutropenia; Prognosis; Severity of Illness Index	2000
Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplantation proceedings, 2001, Volume: 33, Issue:3 Topics: Adrenal Cortex Hormones; Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Magnetic Resonance Imaging; Melphalan; Middle Aged; Multiple Sclerosis; Patient Selection; T-Lymphocytes	2001

Other Studies

4 other study(ies) available for etoposide and MS (Multiple Sclerosis)

Article	Year
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology(R) neuroimmunology & neuroinflammation, 2022, Volume: 9, Issue:6 Topics: Antilymphocyte Serum; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin Heavy Chains; Melphalan; Multiple Sclerosis	2022
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2017, 06-13, Volume: 114, Issue:24 Topics: Animals; Cell Cycle Checkpoints; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Etoposide; Humans; Immune System Diseases; Lymphocyte Activation; Lymphohistiocytosis, Hemophagocytic; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multiple Sclerosis; Proto-Oncogene Proteins c-mdm2; Signal Transduction; T-Lymphocytes; Tumor Suppressor Protein p53	2017
Eliminating encephalitogenic T cells without undermining protective immunity. Journal of immunology (Baltimore, Md. : 1950), 2014, Jan-01, Volume: 192, Issue:1 Topics: Animals; Apoptosis; B-Lymphocytes; CD4-Positive T-Lymphocytes; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Etoposide; Female; Immunologic Memory; Lymphocyte Activation; Lymphocyte Depletion; Lymphocytic choriomeningitis virus; Mice; Multiple Sclerosis; Recurrence; T-Lymphocytes	2014
High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Multiple sclerosis (Houndmills, Basingstoke, England), 2010, Volume: 16, Issue:6 Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Kaplan-Meier Estimate; Male; Melphalan; Multiple Sclerosis; Treatment Outcome	2010